Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

58.83USD
20 Apr 2018
Change (% chg)

$0.19 (+0.32%)
Prev Close
$58.64
Open
$58.86
Day's High
$59.27
Day's Low
$58.67
Volume
3,825,368
Avg. Vol
3,915,961
52-wk High
$66.41
52-wk Low
$52.83

Latest Key Developments (Source: Significant Developments)

Keytruda Monotherapy Met Primary Endpoint In Phase 3 Study, Significantly Improving OS As First-Line Therapy In Locally Advanced Or Metastatic NSCLC Patients Expressing PD-L1 In At Least 1 Pct O
Monday, 9 Apr 2018 06:45am EDT 

April 9 (Reuters) - Merck & Co Inc ::KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD-L1 IN AT LEAST 1 PERCENT OF TUMOR CELLS.SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT.PHASE 3 KEYNOTE-042 TRIAL WILL CONTINUE TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS), WHICH IS A SECONDARY ENDPOINT.  Full Article

Incyte, Merck Provide Update On Phase 3 Study
Friday, 6 Apr 2018 07:30am EDT 

April 6 (Reuters) - Incyte Corp ::INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.STUDY'S SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL ALSO IS NOT EXPECTED TO REACH STATISTICAL SIGNIFICANCE.BASED ON RESULTS, AND AT RECOMMENDATION OF EDMC, PHASE 3 STUDY WILL BE STOPPED.252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA.252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT.  Full Article

Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan
Tuesday, 27 Mar 2018 08:41am EDT 

March 27 (Reuters) - Merck & Co Inc ::MERCK RECEIVES FAST-TRACK DESIGNATION FOR TEPOTINIB IN NON-SMALL CELL LUNG CANCER IN JAPAN.MERCK & CO INC - ‍SAKIGAKE DESIGNATION ENCOMPASSES POSSIBILITY FOR A TARGET REVIEW PERIOD OF 6 MONTHS​.MERCK & CO INC - ‍JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS SAKIGAKE DESIGNATION FOR TEPOTINIB​.  Full Article

GE Appoints Michael Holston As General Counsel
Friday, 23 Feb 2018 10:06am EST 

Feb 23 (Reuters) - General Electric Co ::SAYS MICHAEL HOLSTON NAMED SENIOR VICE PRESIDENT AND GENERAL COUNSEL OF GE‍​.SAYS HOLSTON JOINS GE FROM MERCK.SAYS HOLSTON SUCCEEDS ALEX DIMITRIEF.  Full Article

Merck And Viralytics Announce Acquisition Agreement
Wednesday, 21 Feb 2018 04:00am EST 

Feb 21 (Reuters) - Merck & Co Inc ::MERCK AND VIRALYTICS ANNOUNCE ACQUISITION AGREEMENT, EXPANDING MERCK'S LEADING IMMUNO-ONCOLOGY PIPELINE.MERCK - PROPOSED ACQUISITION VALUES THE TOTAL ISSUED SHARES IN VIRALYTICS AT APPROXIMATELY AUD 502 MILLION (USD 394 MILLION).MERCK - ON COMPLETION OF TRANSACTION, VIRALYTICS WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF MERCK.  Full Article

Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1
Thursday, 15 Feb 2018 06:30am EST 

Feb 15 (Reuters) - Merck & Co Inc ::SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1.MERCK & CO INC - ‍FDA GRANTED ORPHAN DRUG DESIGNATION FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1​.MERCK & CO INC - PHASE II TRIAL RESULTS FOR SELUMETINIB ARE EXPECTED LATER IN 2018.  Full Article

Affimed Reports New Data For AFM13 From Two Separate Clinical Trials
Thursday, 1 Feb 2018 08:30am EST 

Feb 1 (Reuters) - Affimed Nv ::AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS.AFFIMED NV - ‍DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED​.AFFIMED NV - ‍DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS​.AFFIMED NV - ‍EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA​.AFFIMED NV - ‍AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY​.AFFIMED NV - ‍ AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE.  Full Article

PharmAbcine Enters in Collaboration With MSD
Thursday, 1 Feb 2018 07:00am EST 

Feb 1 (Reuters) - Merck & Co Inc ::PHARMABCINE ENTERS COLLABORATION WITH MSD FOCUSED ON CLINICAL EVALUATION OF TTAC-0001 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN RECURRENT GLIOBLASTOMA AND BREAST CANCER.PHARMABCINE SAYS WILL CONDUCT INTERNATIONAL PHASE I/II STUDIES TO EVALUATE POTENTIAL CLINICAL SYNERGY OF COMBINING TTAC-0001 WITH KEYTRUDA.PHARMABCINE INC SAYS HAS ENTERED INTO A COLLABORATIVE AGREEMENT WITH MSD.  Full Article

Prokaryotics Announces Licensing Agreement With Merck For Novel Investigational Antibiotic Candidates
Thursday, 25 Jan 2018 08:30am EST 

Jan 25 (Reuters) - Merck & Co Inc ::PROKARYOTICS ANNOUNCES LICENSING AGREEMENT WITH MERCK FOR NOVEL INVESTIGATIONAL ANTIBIOTIC CANDIDATES.PROKARYOTICS - ANNOUNCES LICENSING AGREEMENT WITH MERCK FOR NOVEL INVESTIGATIONAL ANTIBIOTIC CANDIDATES.PROKARYOTICS - CO GAINS WORLDWIDE RIGHTS TO DEVELOP EARLY PRE-CLINICAL PROGRAMS FOR GRAM-NEGATIVE, GRAM-POSITIVE BACTERIAL CELL ENVELOPE ENZYMES.PROKARYOTICS - SPECIFIC TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints
Tuesday, 16 Jan 2018 06:45am EST 

Jan 16 (Reuters) - Merck & Co Inc ::MERCK'S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (KEYNOTE-189).MERCK & CO INC - PIVOTAL PHASE 3 KEYNOTE-189 TRIAL MET ITS DUAL PRIMARY ENDPOINTS.MERCK & CO INC - ‍SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED​.  Full Article

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.